Immunovant (IMVT) unveiled promising results for an experimental Graves' disease treatment on Thursday. IMVT stock rallied, reversing a recent decline. ...

Investor's Business Daily 12/21/2023 04:09 PM ET

Stock Market Does Sharp About-Face; Dow Breaks Win Streak

Stock market indexes unexpectedly reversed course in afternoon trading Wednesday, sending the major indexes lower by more than 1%. The ...

Investor's Business Daily 12/20/2023 04:33 PM ET

Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart

Argenx (ARGX) stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a ...

Investor's Business Daily 12/20/2023 04:02 PM ET

argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Threshold

argenx ADR (ARGX) had its Relative Strength (RS) Rating upgraded from 79 to 82 Wednesday. When looking for the best ...

Investor's Business Daily 12/06/2023 03:00 AM ET

View All »

IBD Partners

No News Available.

STOCK/COMPANY DATA FOR ARGX

Stock Data

Today's Range
357.55 - 362.54

52-Week Range
327.72 - 550.76

Price % Chg. YTD
-5.31%

Price % Chg. Last 4 Weeks
-8.51%

50-Day Avg. Volume
265,500

Shares Outstanding
58.1 Mil

Float
56.4 Mil

IPO Date
05/18/2017

Investment Bank
Cowen And Company

% Mgmt Owns
2.43%

PE Ratio
0

Dividend Yield
0

Alpha
-0.06

Beta
1.09

Company Fundamentals

EPS Due Date
5/9/2024

EPS % Chg (Last Qtr)
-140%

3 Year EPS Growth Rate
0%

EPS Est % Chg (Current Yr)
61%

Annual ROE
0%

Sales % Chg (Last Qtr)
129%

3-Year Sales Growth Rate
81%

Debt %
0

Market Cap
$20.9 B $21 Bil

Annual Pre -Tax Margin
-163.8%

Sector
medical

Industry Group
Medical-Biomed/Biotech

Industry Group Rank
19